Amgen (AMGN) Q3 FY25 earnings call

Amgen delivered a strong third quarter, marked by robust volume-driven revenue growth across its key therapeutic areas and biosimilar portfolio. The company is advancing a deep pipeline, particularly in obesity with MariTide and cardiovascular disease with Repatha, while also expanding access to its medicines through initiatives like AmgenNow. Management remains focused on innovation, disciplined capital allocation, and executional excellence to sustain long-term growth, despite evolving competitive dynamics for some established products.